1061.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 09:01):

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally...

Stats
Šios dienos apimtis	119 000
Vidutinė apimtis	124 192
Rinkos kapitalizacija	1.35B
EPS	HKD0 ( 2023-08-16 )
Kita pelno data	( HKD0 ) 2024-05-28
Last Dividend	HKD0.0450 ( 2023-08-29 )
Next Dividend	HKD0 ( N/A )
P/E	5.06
ATR14	HKD0.0100 (0.42%)

Essex Bio-Technology Ltd Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Essex Bio-Technology Ltd Finansinės ataskaitos

Annual	2023
Pajamos:	HKD1.71B
Bruto pelnas:	HKD1.54B (90.20 %)
EPS:	HKD0.480

FY	2023
Pajamos:	HKD1.71B
Bruto pelnas:	HKD1.54B (90.20 %)
EPS:	HKD0.480

FY	2022
Pajamos:	HKD1.32B
Bruto pelnas:	HKD1.19B (90.26 %)
EPS:	HKD0.390

FY	2021
Pajamos:	HKD1.64B
Bruto pelnas:	HKD1.40B (85.23 %)
EPS:	HKD0.600

Financial Reports:

No articles found.

Essex Bio-Technology Ltd Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.0400 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.0250 (N/A)	HKD0.0450 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Essex Bio-Technology Ltd Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.38 - Stable (27.62%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0100	2009-04-30
Last Dividend	HKD0.0450	2023-08-29
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	21	--
Total Paid Out	HKD0.602	--
Avg. Dividend % Per Year	0.00%	--
Score	3.61	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.38
Div. Directional Score	9.67	--

Next Divdend (Est)
(2025-01-27)

HKD0.0467 Estimate 11.67 %

Dividend Stability

0.47 Below Average

Dividend Score

3.61

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2778.HK	Ex Dividend Junior	2023-09-15	Semi-Annually	0.00%
1449.HK	Ex Dividend Junior	2023-05-24	Insufficient data to determine frequency	0.00%
0533.HK	Ex Dividend Knight	2023-09-05	Semi-Annually	0.00%
6896.HK	Ex Dividend Junior	2023-06-16	Annually	0.00%
1982.HK	Ex Dividend Junior	2023-07-06	Annually	0.00%
1051.HK	Ex Dividend Junior	2023-06-26	Sporadic	0.00%
0124.HK	No Dividend Player	2023-10-06	Sporadic	0.00%
3396.HK	No Dividend Player	2023-07-03	Annually	0.00%
1599.HK	Ex Dividend Junior	2023-05-31	Annually	0.00%
0639.HK	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.161	1.500	6.77	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0973	1.200	6.76	8.11	[0 - 0.3]
returnOnEquityTTM	0.148	1.500	9.47	10.00	[0.1 - 1]
payoutRatioTTM	0.145	-1.000	8.55	-8.55	[0 - 1]
currentRatioTTM	1.536	0.800	7.32	5.86	[1 - 3]
quickRatioTTM	1.425	0.800	6.32	5.06	[0.8 - 2.5]
cashRatioTTM	0.633	1.500	7.59	10.00	[0.2 - 2]
debtRatioTTM	0.0968	-1.500	8.39	-10.00	[0 - 0.6]
interestCoverageTTM	21.84	1.000	3.02	3.02	[3 - 30]
operatingCashFlowPerShareTTM	0.588	2.00	9.80	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.363	2.00	9.82	10.00	[0 - 20]
debtEquityRatioTTM	0.142	-1.500	9.43	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.902	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.185	1.000	8.29	8.29	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.220	1.000	4.33	4.33	[0.2 - 2]
assetTurnoverTTM	0.604	0.800	9.31	7.45	[0.5 - 2]
Total Score				12.97

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.74	1.000	9.62	0	[1 - 100]
returnOnEquityTTM	0.148	2.50	9.66	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.363	2.00	9.88	10.00	[0 - 30]
dividendYielPercentageTTM	3.04	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.588	2.00	9.80	10.00	[0 - 30]
payoutRatioTTM	0.145	1.500	8.55	-8.55	[0 - 1]
pegRatioTTM	0.158	1.500	-2.28	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.196	1.000	7.61	0	[0.1 - 0.5]
Total Score				6.38

Essex Bio-Technology Ltd

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.